Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Heart Failure in Zero Gravity—External Constraint and Cardiac Hemodynamics
Hearon, Christopher M. , Manferdelli, Giorgio , Shah, Aman , Tayon, Kevin G. , Sarma, Satyam , Levine, Benjamin D., MacNamara, James P. , Pandey, Ambarish , Levine, Benjamin D.

JAMA Cardiology | November 16, 2024 | Volume: 10 | Issue: 1 | Pages: 98

10.1001/jamacardio.2024.4596 | PMID 39549275 Get It

In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.
The Outcomes of Adenovirus Infection in Kidney Transplant Recipients
Me, Hay Me , Nair, S. , Schinstock, Carrie A. , Jarmi, Tambi , Zhang, Nan , Budhiraja, Pooja , Kodali, Lavanya , Vikram, Holenarasipur R. , Mour, Girish , Nair, Sumi S , Vikram, Holenarasipur R. , Schinstock, Carrie , Budhiraja, Pooja , Jarmi, Tambi , Mour, Girish K

Transplant Infectious Disease | November 16, 2024 | Volume: 27 | Issue: 1 | Pages: No page available

10.1111/tid.14409 | PMID 39549255 Get It

ABSTRACTBackgroundAdenovirus (ADV) infection can lead to significant morbidity and mortality in immunocompromised patients, particularly in those with hematopoietic stem cells or solid organ transplants. The incidence of ADV infection in kidney transplant (KT) is not well‐defined as ADV is often asymptomatic and not routinely checked.MethodsThis retrospective case‐series study included KT and simultaneous pancreas‐KT (SPKT) recipients from January 1, 2008, to January 31, 2024, across three Mayo Clinic sites (Arizona, Florida, and Minnesota) with symptomatic adenovirus polymerase chain reaction cases. The primary outcomes were allograft function at various intervals post‐ADV infection, allograft, and patient survival.ResultsWe report one of the largest multi‐site case series regarding outcomes of ADV in KT with 17 patients. The median time to ADV infection was 30 weeks (5–74). Five patients (29%) developed disseminated infection. Nine patients (53%) of the entire cohort experienced graft loss within a median of 35 (4–168) weeks, with four (44%) of graft loss attributed to ADV. Nine patients (53%) developed rejections post‐ADV infection with a median of 4 (2–8) weeks after resolution. One patient died from acute hypoxic respiratory failure from ADV infection.ConclusionADV should be considered in KT/SPKT patients with renal dysfunction, hematuria, and with or without fever. Despite the low mortality rate, there is a significant risk of graft loss and rejection after ADV infection. It is crucial to screen for ADV and develop intervention strategies for treatment. Further multicenter studies are needed to better define, stage, and manage ADV infection. image
Hypercapnia impacts neural drive and timing of diaphragm neuromotor control
Khurram, Obaid U. , Kantor-Gerber, Maximilian J., Mantilla, Carlos B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B , Khurram, Obaid U

Journal of Neurophysiology | November 16, 2024 | Volume: 132 | Issue: 6 | Pages: 1966-1976

10.1152/jn.00466.2024 | PMID 39548981 Get It

The neuromotor control of the diaphragm muscle (DIAm) in response to hypercapnia is not well understood. We show that both the number of motor units recruited and their discharge rates increase with hypercapnia, consistent with increased respiratory drive during hypercapnia. Potentially in response to this increased drive, the greatest effect of hypercapnia is on during the postinspiratory (descending) ramp of DIAm EMG activity, which shortens to facilitate higher respiratory rates.
Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in Africa
Odukoya, Lateef A , Darko, Kwadwo , Zerd, Francis , Ghomsi, Nathalie , Kabare, Gloria , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Kitange, Gaspar J. , Akinjo, Andrea O , Badmos, Kabir, Idowu, Olufemi Emmanuel , Karekezi, Claire , Edrick, Elias, Katasi, Victoria Mwebe , Magambo, Margreth, Magoha, Michael, Ngaiza, Advera , Okemwa, Minda, Osei‐Tutu, Lawrence, Petershie, Bernard, Yevudza, W Elorm , Anunobi, C C , Tiamiyu, Liadi, Gankpé, Gbètoho Fortuné, Heronima, Kashaigili, Higgins, Dominique, Schroeder, Kristin, Totimeh, Teddy , Cheserem, Beverly , Gankpé, Fortuné Gbètoho , Schroeder, Kristin , Jenkins, RB , Karekezi, Claire , Brown, Desmond A., Huse, Jason T. , Balogun, James , Schroeder, Kristin , Zerd, Francis , Odukoya, Lateef A , Darko, Kwadwo , Idowu, Olufemi E , Kamson, David , Bankole, Olufemi , Ekhator, Chukwuyem , Brown, Desmond , LLEWELLYN, HENRY J. , Barrie, Umaru , Nyalundja, Arsène Daniel , Schroeder, Kristin, Etame, Arnold B. , Fonkem, Ekokobe

Neuro-Oncology Advances | November 16, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae198 | PMID 39659834 Get It

Abstract Background Brain tumors represent a significant global health challenge, with rising incidence and mortality impacting individuals worldwide and contributing to cancer-related morbidity and mortality. In Africa, this burden is exacerbated by limited access to advanced diagnostics, treatment options, and multidisciplinary care, compounded by the absence of standardized cancer registration and tumor biobanking. The introduction of molecular diagnostics, as outlined in the 2021 World Health Organization central nervous system (CNS) tumor classification, adds complexity to brain tumor management, particularly in regions with scarce resources. Methods To address these issues, the Brain Tumor Consortium for Africa (BTCA) was established in 2023, bringing together experts to improve CNS tumor diagnosis, patient care, and research. The initial project, conducted via an electronic questionnaire, aimed to assess neuro-oncology capacity across Sub-Saharan Africa. Results The study revealed significant gaps, with a limited number of institutions incorporating molecular subtyping into their diagnostic algorithms. The consortium’s efforts focus on enhancing local data use, informing public policy, and promoting collaboration to advance neuro-oncology practices in Africa. By fostering a network enlisting the expertise of collaborators in the fields of neurosurgery, neurology, neuropathology, anatomic pathology, and medical and radiation oncology, the BTCA seeks to improve brain tumor management through better diagnostics, infrastructure, and policy advocacy. Future directions include expanding molecular diagnostic capabilities, standardizing brain tumor biobanking, enhancing data collection, and advocating for improved brain tumor care in national health agendas. Conclusions The BTCA represents a pioneering model of collaboration and innovation in addressing the unique challenges of brain tumor care in Africa.
Orofacial Granulomatosis and Crohn's Disease: A Case Series
Urquhart, Siri A. , Kim, Grace Y. , Anderson, Katelyn , Anderson, Katelyn R, Chedid, Victor G , Chedid, Victor

ACG Case Reports Journal | November 16, 2024 | Volume: 11 | Issue: 11 | Pages: e01559

10.14309/crj.0000000000001559 | PMID 39559789 Get It

ABSTRACT Orofacial granulomatosis (OFG) is a rare syndrome that can occur in association with Crohn's disease (CD). The electronic medical record was searched for “OFG” and “CD.” A total of 297 patients were identified, and relevant data were abstracted. Five patients met inclusion criteria. Most (80%) had ileocolonic CD with nonstricturing/nonpenetrating phenotype. The most common treatments included intralesional corticosteroids (4 patients), oral corticosteroids (3 patients), and anti-TNF agents, specifically infliximab (3 patients). Intralesional corticosteroid administration was followed by partial response in 3 patients, but recurrences were common following initial injection. One patient had no response to topical or oral corticosteroids, antihistamines, or oral antibiotics, but partial response to intralesional corticosteroids and infliximab. None of the patients had complete response to any therapies directed at this condition. OFG may be characterized by partial response, often requiring long-term therapy. Additional investigations into novel treatments may improve future clinical outcomes.
Two‐Stage Recruitment Design to Reduce Magnetic Resonance Imaging Screening Cost for a Theoretical Clinical Trial of White Matter Hyperintensity Progression
Egle, Marco , Johri, Mohini, Power, Melinda C. , Deal, Jennifer A. , Jack, Clifford R. , Sullivan, Kevin , Mosley, Thomas H. , Mosley, Thomas H. , Sullivan, Kevin J , Gottesman, Rebecca F , Jack, Clifford R , Deal, Jennifer A , Egle, Marco , Johri, Mohini, Gottesman, Rebecca F.

Journal of the American Heart Association | November 16, 2024 | Volume: 13 | Issue: 22 | Pages: No page available

10.1161/jaha.124.036140 | PMID 39547991 Get It

Background White matter hyperintensities (WMH) and their progression are associated with risk of dementia and stroke, so are an important target for clinical trials. The cost of broad magnetic resonance imaging (MRI) screening to identify eligible individuals, however, limits the feasibility of designing clinical trials targeting WMH. A low‐cost retinal or clinical screening measure before MRI could reduce recruitment costs versus an MRI‐only screening design in a hypothetical clinical trial. Methods and Results Data from the Atherosclerosis Risk in Communities study with valid retinal and WMH measurements ( N =1311) were used. To identify a population at greater likelihood of significant WMH on MRI and thus reduce the number of screening MRIs required, we evaluated 3 theoretical prescreening measures: (1) retinal, (2) clinical, (3) combined clinical‐retinal. Given a target sample for clinical trials ( N =646), we calculated screening sample sizes based on the proportion within the population having an elevated score for each prescreening measure (separately) multiplied by the proportion of significant WMH among those with that prescreening feature. Recruitment costs were calculated using estimated retinal and MRI cost estimates. Compared with the estimated cost of MRI‐only screening (>$4.24 million, requiring MRI on 6526 participants), prescreening for a high clinical score resulted in total cost of $2.47 million, with an initial screening group of 52 778 participants, with MRI in 3801. A high clinical‐retinal score cutoff resulted in costs of $2.9 million while requiring 13 572 participants, with 3801 completing MRI. Conclusions A 2‐stage design with low‐cost prescreening measures is a promising approach, resulting in reduced theoretical recruitment costs compared with an MRI‐only design.
Evaluating the metformin use on type 2 diabetes prevention in high-risk populations in primary care
Ramírez-Torres, Andony I., Ruiz-Hernández, Fernando G. , Omaña, Gabriela Guadalupe Elizondo, García-Hernández, Rosa María , Peña, P. García de la, Rojo-Garza, Sandra S., Ruiz Hernandez, Fernando Gerardo , Álvarez‐Villalobos, Neri Alejandro , García-Hernández, Rosa M., Peña, Pablo J. Moreno

Journal of Family Medicine and Primary Care | November 16, 2024 | Volume: 13 | Issue: 11 | Pages: 5002-5008

10.4103/jfmpc.jfmpc_552_24 | PMID 39722964 Get It

A BSTRACT Purpose/Background: To identify the proportion of patients with prediabetes who have prescribed metformin and factors related to doing so as a preventive measure for diabetes in primary care at a Family Medicine Unit in northeastern Mexico. Methods: This retrospective observational study included 372 adults who met the criteria for prediabetes diagnosis according to the American Diabetes Association. Data was collected from medical records from January 2020 to December 2021. Possible associations between the variables of interest and the prescription of metformin were tested via hypothesis tests, furthermore, binary logistic regression was performed. Results: Nearly 85% of the patients met at least one criterion for receiving metformin according to ADA recommendations, but only 60% of them were prescribed this medication. Patients with metformin prescriptions differed from those without in aspects such as having a documented diagnosis of prediabetes in their medical records, a higher BMI, and higher glucose levels. Conclusions: Almost one out of two patients with a high risk of type 2 diabetes are not treated with metformin as a preventive measure. Factors associated with metformin prescription included a high BMI, elevated baseline glucose levels, and a prediabetes diagnosis in the medical record. These findings suggest the need for studies to evaluate physicians’ reasons for different treatments and implementation of recommendations for type 2 diabetes prevention in patients with prediabetes in primary health care.
Minimum cochlear dose impacts hearing after radiosurgery for sporadic vestibular schwannoma
Khandalavala, Karl R. , Dornhoffer, James R. , Babajanian, Eric E. , Daher, Ghazal S. , Marinelli, John P. , Brown, Paul D. , Lohse, Christine M. , Carlson, Matthew L., Link, Michael J., Morshed, Ramin A. , Carlson, Matthew L. , Link, Michael J.

Journal of Neurosurgery | November 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3171/2024.7.jns24789 | PMID 39546773 Get It

OBJECTIVE It is uncertain which cochlear dose parameters significantly impact hearing after stereotactic radiosurgery (SRS) for sporadic vestibular schwannoma (VS). The objective of this study was to determine the impact of cochlear dose parameters on hearing outcomes for patients with serviceable hearing (SH). METHODS This was a historical cohort study performed at a single tertiary center that included patients with sporadic VS and SH who underwent single-session Gamma Knife radiosurgery treatment from 2007 to 2022. Associations of cochlear dose parameters with time to non-SH and rates of change in pure-tone average (PTA) and word recognition score (WRS) following SRS were assessed. RESULTS A total of 205 patients with SH underwent SRS for a sporadic VS. At SRS, 54 (26%) tumors were confined to the internal auditory canal and 151 (74%) extended into the cerebellopontine angle. At 2, 5, and 10 years following SRS, 62%, 37%, and 15% of patients maintained SH, respectively. The median time to non-SH was 1.8 years. The median rates of change in PTA and WRS were 6.0 dB of hearing loss per year and −6.5% per year, respectively. In a multivariable analysis, each 1-Gy increase in minimum cochlear dose was significantly associated with time to non-SH (HR 1.5, 95% CI 1.2–1.9), rate of change in PTA decibel hearing loss per year (parameter estimate [PE] 3.4, 95% CI 0.6–6.2), and rate of change in WRS percentage per year (PE −6.4, 95% CI −11.2 to −1.5). The associations of each 1-Gy increase in mean cochlear dose with hearing outcomes were only significant among patients with class B hearing (time to non-SH HR 1.3, 95% CI 1.1–1.6; rate of change in PTA PE 3.6, 95% CI 1.2–5.9; and rate of change in WRS PE −5.7, 95% CI −9.7 to −1.7). CONCLUSIONS The minimum cochlear dose impacts hearing outcomes after SRS for VS and should be considered in radiosurgical treatment planning. In this cohort, the mean cochlear dose was only associated with hearing outcomes in the subgroup of patients with class B hearing at SRS.
Activation of Hippocampal Neuronal NADPH Oxidase NOX2 Promotes Depressive-Like Behaviour and Cognition Deficits in Chronic Restraint Stress Mouse Model
Zuo, Zejie , Zhang, Hongyang , Li, Z. B. , Hu, Haojie , Yao, Zhibin , Li, Z. B. , Qi, Fangfang , Yang, Junhua

Pharmacopsychiatry | November 15, 2024 | Volume: 58 | Issue: 03 | Pages: 117-126

10.1055/a-2429-4023 | PMID 39547705 Get It

Abstract Background Nicotinamide adenosine dinucleotide phosphate oxidases (NOX) play important roles in mediating stress-induced depression. Three NOX isotypes are expressed mainly in the brain: NOX2, NOX3 and NOX4. In this study, the expression and cellular sources of these NOX isoforms was investigated in the context of stress-induced depression. Methods Chronic restraint stress (CRS)-induced depressive-like behaviour and cognitive deficits were evaluated by tail suspension tests, forced swimming tests and the Morris water maze test. Hippocampal NOX expression was determined by immunofluorescence staining and western blotting. The hippocampal levels of the brain-derived neurotrophic factor (BDNF) mRNA were determined via quantitative real-time –polymerase chain reaction. Glucocorticoid levels in the hippocampus were measured using ELISA kits. Results In the mouse CRS model, a significant increase in NOX2 expression was observed in the hippocampus, whereas no significant changes in NOX3 and NOX4 expression were detected. Next, NOX2 expression was primarily localised to neurons (NeuN+) but not microglia (Iba-1+) or astrocytes (GFAP+). Treatment with gp91ds-tat, a specific NOX2 inhibitor, effectively mitigated the behavioural deficits induced by CRS. The decreased expression of the BDNF mRNA in the hippocampus of CRS mice was restored upon gp91ds-tat treatment. A positive correlation was identified between neuronal NOX2 expression and serum glucocorticoid levels. Conclusions Our study indicated that neuronal NOX2 may be a critical mediator of depression-like behaviours and spatial cognitive deficits in mice subjected to CRS. Blockade of NOX2 signalling may be a promising therapeutic strategy for depression.